DDrare: Database of Drug Development for Rare Diseases

Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

A B C D E F G H I J K L M N O PQR S T U V WXYZother

121 / 286 pathways

No.	KEGG PATHWAY On map, Yellow: Drug target, Red: All disease-related	KEGG GENES	KEGG DRUG	DrugBank	指定難病告示番号
1	Adipocytokine signaling pathway 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
2	Adipocytokine signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
3	Adipocytokine signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
4	African trypanosomiasis 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
5	African trypanosomiasis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
6	African trypanosomiasis 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
7	African trypanosomiasis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
8	African trypanosomiasis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
9	AGE-RAGE signaling pathway in diabetic complications 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
10	AGE-RAGE signaling pathway in diabetic complications 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
11	AGE-RAGE signaling pathway in diabetic complications 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
12	AGE-RAGE signaling pathway in diabetic complications 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
13	AGE-RAGE signaling pathway in diabetic complications 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
14	Allograft rejection 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
15	Allograft rejection 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
16	Allograft rejection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
17	Allograft rejection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
18	Alzheimer disease 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
19	Alzheimer disease 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
20	Alzheimer disease 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
21	Alzheimer disease 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
22	Alzheimer disease 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
23	Amoebiasis 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
24	Amoebiasis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
25	Amoebiasis 💬	2件: IL1R1, IL1R2 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
26	Amoebiasis 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
27	Amoebiasis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
28	Amoebiasis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
29	Amphetamine addiction 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
30	Amyotrophic lateral sclerosis 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
31	Amyotrophic lateral sclerosis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
32	Amyotrophic lateral sclerosis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
33	Antifolate resistance 💬	2件: DHFR, DHFR2 💬	D00142 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
34	Antifolate resistance 💬	2件: DHFR, DHFR2 💬	D02115 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
35	Antifolate resistance 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
36	Antifolate resistance 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
37	Antifolate resistance 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
38	Antifolate resistance 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
39	Antigen processing and presentation 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
40	Antigen processing and presentation 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
41	Apoptosis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
42	Apoptosis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
43	Asthma 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
44	Asthma 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
45	Autoimmune thyroid disease 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
46	Axon guidance 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
47	B cell receptor signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
48	Biosynthesis of cofactors 💬	2件: DHFR, DHFR2 💬	D00142 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
49	Biosynthesis of cofactors 💬	2件: DHFR, DHFR2 💬	D02115 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
50	C-type lectin receptor signaling pathway 💬	3件: IL12A, IL12B, IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
51	C-type lectin receptor signaling pathway 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
52	C-type lectin receptor signaling pathway 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
53	C-type lectin receptor signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
54	C-type lectin receptor signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
55	C-type lectin receptor signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
56	C-type lectin receptor signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
57	Calcium signaling pathway 💬	2件: EDNRA, EDNRB 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
58	Calcium signaling pathway 💬	2件: EDNRA, EDNRB 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
59	Calcium signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
60	cAMP signaling pathway 💬	1件: EDNRA 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
61	cAMP signaling pathway 💬	1件: EDNRA 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
62	Cell adhesion molecules 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
63	Cell adhesion molecules 💬	1件: PDCD1 💬	D10316 💬	Nivolumab	12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
64	Cellular senescence 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
65	Cellular senescence 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
66	cGMP-PKG signaling pathway 💬	2件: EDNRA, EDNRB 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
67	cGMP-PKG signaling pathway 💬	2件: EDNRA, EDNRB 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
68	cGMP-PKG signaling pathway 💬	1件: OPRD1 💬	D02095 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
69	cGMP-PKG signaling pathway 💬	1件: OPRD1 💬	D05113 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
70	cGMP-PKG signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
71	Chagas disease 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
72	Chagas disease 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
73	Chagas disease 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
74	Chagas disease 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
75	Chagas disease 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
76	Chemokine signaling pathway 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
77	Cholinergic synapse 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
78	Coronavirus disease - COVID-19 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
79	Coronavirus disease - COVID-19 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
80	Coronavirus disease - COVID-19 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
81	Coronavirus disease - COVID-19 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
82	Coronavirus disease - COVID-19 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
83	Coronavirus disease - COVID-19 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
84	Coronavirus disease - COVID-19 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
85	Coronavirus disease - COVID-19 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
86	Coronavirus disease - COVID-19 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
87	Cytokine-cytokine receptor interaction 💬	1件: CSF2RA 💬	D09930 💬	Mavrilimumab	2件: 41, 46 💬
88	Cytokine-cytokine receptor interaction 💬	1件: CSF3R 💬	D03235 💬	Filgrastim	33件: 2 , 6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
89	Cytokine-cytokine receptor interaction 💬	3件: IL12A, IL12B, IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
90	Cytokine-cytokine receptor interaction 💬	1件: IL17A 💬	D09967 💬	Secukinumab	7件: 13, 37, 41, 46, 160, 269, 271 💬
91	Cytokine-cytokine receptor interaction 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
92	Cytokine-cytokine receptor interaction 💬	2件: IL1R1, IL1R2 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
93	Cytokine-cytokine receptor interaction 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
94	Cytokine-cytokine receptor interaction 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
95	Cytokine-cytokine receptor interaction 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
96	Cytokine-cytokine receptor interaction 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
97	Cytokine-cytokine receptor interaction 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
98	Cytokine-cytokine receptor interaction 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
99	Cytosolic DNA-sensing pathway 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
100	Cytosolic DNA-sensing pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
101	Dilated cardiomyopathy 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
102	Dilated cardiomyopathy 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
103	Dopaminergic synapse 💬	3件: PPP3CA, PPP3CB, PPP3CC 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
104	EGFR tyrosine kinase inhibitor resistance 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
105	EGFR tyrosine kinase inhibitor resistance 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
106	EGFR tyrosine kinase inhibitor resistance 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
107	EGFR tyrosine kinase inhibitor resistance 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
108	EGFR tyrosine kinase inhibitor resistance 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
109	Endocrine and other factor-regulated calcium reabsorption 💬	1件: VDR 💬	D01518 💬	Alfacalcidol	6件: 41, 46, 49, 50, 96, 235 💬
110	Epstein-Barr virus infection 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
111	Epstein-Barr virus infection 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
112	Epstein-Barr virus infection 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
113	Epstein-Barr virus infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
114	Epstein-Barr virus infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
115	Estrogen signaling pathway 💬	1件: OPRM1 💬	D02095 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
116	Estrogen signaling pathway 💬	1件: OPRM1 💬	D05113 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
117	Fc epsilon RI signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
118	Fc epsilon RI signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
119	Fluid shear stress and atherosclerosis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
120	Fluid shear stress and atherosclerosis 💬	2件: IL1R1, IL1R2 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
121	Fluid shear stress and atherosclerosis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
122	Fluid shear stress and atherosclerosis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
123	Folate biosynthesis 💬	2件: DHFR, DHFR2 💬	D00142 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
124	Folate biosynthesis 💬	2件: DHFR, DHFR2 💬	D02115 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
125	FoxO signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
126	Glucagon signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
127	Glutamatergic synapse 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
128	Graft-versus-host disease 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
129	Graft-versus-host disease 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
130	Graft-versus-host disease 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
131	Graft-versus-host disease 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
132	Graft-versus-host disease 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
133	Growth hormone synthesis, secretion and action 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
134	Hematopoietic cell lineage 💬	1件: CSF2RA 💬	D09930 💬	Mavrilimumab	2件: 41, 46 💬
135	Hematopoietic cell lineage 💬	1件: CSF3R 💬	D03235 💬	Filgrastim	33件: 2 , 6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
136	Hematopoietic cell lineage 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
137	Hematopoietic cell lineage 💬	2件: IL1R1, IL1R2 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
138	Hematopoietic cell lineage 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
139	Hematopoietic cell lineage 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
140	Hematopoietic cell lineage 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
141	Hematopoietic cell lineage 💬	1件: MS4A1 💬	D02994 💬	Rituximab	47件: 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
142	Hematopoietic cell lineage 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
143	Hematopoietic cell lineage 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
144	Hepatitis B 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
145	Hepatitis B 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
146	Hepatitis B 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
147	Hepatitis B 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
148	Hepatitis B 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
149	Hepatitis C 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
150	Hepatitis C 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
151	Hepatitis C 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
152	Hepatitis C 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
153	Herpes simplex virus 1 infection 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
154	Herpes simplex virus 1 infection 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
155	Herpes simplex virus 1 infection 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
156	Herpes simplex virus 1 infection 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
157	Herpes simplex virus 1 infection 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
158	Herpes simplex virus 1 infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
159	Herpes simplex virus 1 infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
160	HIF-1 signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
161	HIF-1 signaling pathway 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
162	HIF-1 signaling pathway 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
163	Human cytomegalovirus infection 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
164	Human cytomegalovirus infection 💬	1件: IL1R1 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
165	Human cytomegalovirus infection 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
166	Human cytomegalovirus infection 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
167	Human cytomegalovirus infection 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
168	Human cytomegalovirus infection 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
169	Human cytomegalovirus infection 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
170	Human cytomegalovirus infection 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
171	Human cytomegalovirus infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
172	Human cytomegalovirus infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
173	Human immunodeficiency virus 1 infection 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
174	Human immunodeficiency virus 1 infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
175	Human immunodeficiency virus 1 infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
176	Human papillomavirus infection 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
177	Human papillomavirus infection 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
178	Human papillomavirus infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
179	Human papillomavirus infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
180	Human T-cell leukemia virus 1 infection 💬	1件: FDPS 💬	D00939 💬	Alendronic acid	7件: 19, 41, 46, 50, 271, 274, 299 💬
181	Human T-cell leukemia virus 1 infection 💬	1件: FDPS 💬	D07119 💬	Alendronic acid	7件: 19, 41, 46, 50, 271, 274, 299 💬
182	Human T-cell leukemia virus 1 infection 💬	2件: IL1R1, IL1R2 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
183	Human T-cell leukemia virus 1 infection 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
184	Human T-cell leukemia virus 1 infection 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
185	Human T-cell leukemia virus 1 infection 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
186	Human T-cell leukemia virus 1 infection 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
187	Human T-cell leukemia virus 1 infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
188	Human T-cell leukemia virus 1 infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
189	Hypertrophic cardiomyopathy 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
190	Hypertrophic cardiomyopathy 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
191	Hypertrophic cardiomyopathy 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
192	IL-17 signaling pathway 💬	1件: IL17A 💬	D09967 💬	Secukinumab	7件: 13, 37, 41, 46, 160, 269, 271 💬
193	IL-17 signaling pathway 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
194	IL-17 signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
195	IL-17 signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
196	IL-17 signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
197	Inflammatory bowel disease 💬	3件: IL12A, IL12B, IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
198	Inflammatory bowel disease 💬	1件: IL17A 💬	D09967 💬	Secukinumab	7件: 13, 37, 41, 46, 160, 269, 271 💬
199	Inflammatory bowel disease 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
200	Inflammatory bowel disease 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
201	Inflammatory bowel disease 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
202	Inflammatory bowel disease 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
203	Inflammatory bowel disease 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
204	Inflammatory mediator regulation of TRP channels 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
205	Inflammatory mediator regulation of TRP channels 💬	1件: IL1R1 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
206	Influenza A 💬	1件: FDPS 💬	D00939 💬	Alendronic acid	7件: 19, 41, 46, 50, 271, 274, 299 💬
207	Influenza A 💬	1件: FDPS 💬	D07119 💬	Alendronic acid	7件: 19, 41, 46, 50, 271, 274, 299 💬
208	Influenza A 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
209	Influenza A 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
210	Influenza A 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
211	Influenza A 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
212	Influenza A 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
213	Influenza A 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
214	Influenza A 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
215	Insulin resistance 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
216	Insulin resistance 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
217	Insulin resistance 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
218	Intestinal immune network for IgA production 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
219	Intestinal immune network for IgA production 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
220	JAK-STAT signaling pathway 💬	1件: CSF2RA 💬	D09930 💬	Mavrilimumab	2件: 41, 46 💬
221	JAK-STAT signaling pathway 💬	1件: CSF3R 💬	D03235 💬	Filgrastim	33件: 2 , 6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
222	JAK-STAT signaling pathway 💬	3件: IL12A, IL12B, IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
223	JAK-STAT signaling pathway 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
224	JAK-STAT signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
225	JAK-STAT signaling pathway 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
226	JAK-STAT signaling pathway 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
227	JAK-STAT signaling pathway 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
228	JAK-STAT signaling pathway 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
229	Kaposi sarcoma-associated herpesvirus infection 💬	1件: CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
230	Kaposi sarcoma-associated herpesvirus infection 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
231	Kaposi sarcoma-associated herpesvirus infection 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
232	Kaposi sarcoma-associated herpesvirus infection 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
233	Kaposi sarcoma-associated herpesvirus infection 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
234	Legionellosis 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
235	Legionellosis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
236	Legionellosis 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
237	Legionellosis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
238	Legionellosis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
239	Leishmaniasis 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
240	Leishmaniasis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
241	Leishmaniasis 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
242	Leishmaniasis 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
243	Leishmaniasis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
244	Leishmaniasis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
245	Long-term potentiation 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
246	Malaria 💬	1件: IL12A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
247	Malaria 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
248	Malaria 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
249	Malaria 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
250	Malaria 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
251	MAPK signaling pathway 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
252	MAPK signaling pathway 💬	1件: IL1R1 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
253	MAPK signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
254	MAPK signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
255	MAPK signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
256	Measles 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
257	Measles 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
258	Measles 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
259	Measles 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
260	Measles 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
261	Melanogenesis 💬	1件: EDNRB 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
262	Melanogenesis 💬	1件: EDNRB 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
263	Metabolic pathways 💬	2件: DHFR, DHFR2 💬	D00142 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
264	Metabolic pathways 💬	2件: DHFR, DHFR2 💬	D02115 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
265	Metabolic pathways 💬	1件: FDPS 💬	D00939 💬	Alendronic acid	7件: 19, 41, 46, 50, 271, 274, 299 💬
266	Metabolic pathways 💬	1件: FDPS 💬	D07119 💬	Alendronic acid	7件: 19, 41, 46, 50, 271, 274, 299 💬
267	Mineral absorption 💬	1件: VDR 💬	D01518 💬	Alfacalcidol	6件: 41, 46, 49, 50, 96, 235 💬
268	Morphine addiction 💬	1件: OPRM1 💬	D02095 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
269	Morphine addiction 💬	1件: OPRM1 💬	D05113 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
270	mTOR signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
271	mTOR signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
272	Natural killer cell mediated cytotoxicity 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
273	Natural killer cell mediated cytotoxicity 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
274	Natural killer cell mediated cytotoxicity 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
275	Necroptosis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
276	Necroptosis 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
277	Necroptosis 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
278	Necroptosis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
279	Necroptosis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
280	Neuroactive ligand-receptor interaction 💬	2件: EDNRA, EDNRB 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
281	Neuroactive ligand-receptor interaction 💬	2件: EDNRA, EDNRB 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
282	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D00407 💬	Methylprednisolone	44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
283	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D00751 💬	Methylprednisolone	44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
284	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D00979 💬	Methylprednisolone	44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
285	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D05000 💬	Methylprednisolone	44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
286	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D05001 💬	Methylprednisolone	44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
287	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D05002 💬	Methylprednisolone	44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
288	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D00472 💬	Prednisolone	40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
289	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D00980 💬	Prednisolone	40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
290	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D00981 💬	Prednisolone	40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
291	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D00982 💬	Prednisolone	40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
292	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D01239 💬	Prednisolone	40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
293	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D01998 💬	Prednisolone	40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
294	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D02156 💬	Prednisolone	40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
295	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D03301 💬	Prednisolone	40件: 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
296	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D00473 💬	Prednisone	47件: 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬
297	Neuroactive ligand-receptor interaction 💬	1件: NR3C1 💬	D08416 💬	Prednisone acetate	6件: 35, 40, 41, 49, 162, 224 💬
298	Neuroactive ligand-receptor interaction 💬	3件: OPRD1, OPRK1, OPRM1 💬	D02095 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
299	Neuroactive ligand-receptor interaction 💬	3件: OPRD1, OPRK1, OPRM1 💬	D05113 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
300	NF-kappa B signaling pathway 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
301	NF-kappa B signaling pathway 💬	1件: IL1R1 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
302	NF-kappa B signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
303	NF-kappa B signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
304	NOD-like receptor signaling pathway 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
305	NOD-like receptor signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
306	NOD-like receptor signaling pathway 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
307	NOD-like receptor signaling pathway 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
308	NOD-like receptor signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
309	NOD-like receptor signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
310	Non-alcoholic fatty liver disease 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
311	Non-alcoholic fatty liver disease 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
312	Non-alcoholic fatty liver disease 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
313	Non-alcoholic fatty liver disease 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
314	Non-alcoholic fatty liver disease 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
315	Non-alcoholic fatty liver disease 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
316	One carbon pool by folate 💬	2件: DHFR, DHFR2 💬	D00142 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
317	One carbon pool by folate 💬	2件: DHFR, DHFR2 💬	D02115 💬	Methotrexate	35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
318	Oocyte meiosis 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
319	Osteoclast differentiation 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
320	Osteoclast differentiation 💬	1件: IL1R1 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
321	Osteoclast differentiation 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
322	Osteoclast differentiation 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
323	Osteoclast differentiation 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
324	Osteoclast differentiation 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
325	Osteoclast differentiation 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
326	Oxytocin signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
327	Pancreatic cancer 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
328	Pancreatic cancer 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
329	Parathyroid hormone synthesis, secretion and action 💬	1件: VDR 💬	D01518 💬	Alfacalcidol	6件: 41, 46, 49, 50, 96, 235 💬
330	Pathogenic Escherichia coli infection 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
331	Pathogenic Escherichia coli infection 💬	1件: IL1R1 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
332	Pathogenic Escherichia coli infection 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
333	Pathogenic Escherichia coli infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
334	Pathogenic Escherichia coli infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
335	Pathways in cancer 💬	1件: CSF2RA 💬	D09930 💬	Mavrilimumab	2件: 41, 46 💬
336	Pathways in cancer 💬	1件: CSF3R 💬	D03235 💬	Filgrastim	33件: 2 , 6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
337	Pathways in cancer 💬	2件: EDNRA, EDNRB 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
338	Pathways in cancer 💬	2件: EDNRA, EDNRB 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
339	Pathways in cancer 💬	3件: IL12A, IL12B, IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
340	Pathways in cancer 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
341	Pathways in cancer 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
342	Pathways in cancer 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
343	Pathways in cancer 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
344	Pathways in cancer 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
345	Pathways in cancer 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
346	Pathways of neurodegeneration - multiple diseases 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
347	Pathways of neurodegeneration - multiple diseases 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
348	Pathways of neurodegeneration - multiple diseases 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
349	Pathways of neurodegeneration - multiple diseases 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
350	Pathways of neurodegeneration - multiple diseases 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
351	PD-L1 expression and PD-1 checkpoint pathway in cancer 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
352	PD-L1 expression and PD-1 checkpoint pathway in cancer 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
353	PD-L1 expression and PD-1 checkpoint pathway in cancer 💬	1件: PDCD1 💬	D10316 💬	Nivolumab	12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
354	PD-L1 expression and PD-1 checkpoint pathway in cancer 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
355	Pertussis 💬	3件: IL12A, IL12B, IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
356	Pertussis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
357	Pertussis 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
358	Pertussis 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
359	Pertussis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
360	Pertussis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
361	PI3K-Akt signaling pathway 💬	1件: CSF3R 💬	D03235 💬	Filgrastim	33件: 2 , 6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
362	PI3K-Akt signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
363	PI3K-Akt signaling pathway 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
364	PI3K-Akt signaling pathway 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
365	PI3K-Akt signaling pathway 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
366	PI3K-Akt signaling pathway 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
367	Prion disease 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
368	Prion disease 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
369	Prion disease 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
370	Prion disease 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
371	Prion disease 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
372	Prolactin signaling pathway 💬	1件: JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
373	Prostate cancer 💬	1件: IL1R2 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
374	Proteoglycans in cancer 💬	1件: IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
375	Proteoglycans in cancer 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
376	Proteoglycans in cancer 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
377	Relaxin signaling pathway 💬	1件: EDNRB 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
378	Relaxin signaling pathway 💬	1件: EDNRB 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
379	Renin secretion 💬	1件: EDNRA 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
380	Renin secretion 💬	1件: EDNRA 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
381	Renin secretion 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
382	Rheumatoid arthritis 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
383	Rheumatoid arthritis 💬	1件: IL17A 💬	D09967 💬	Secukinumab	7件: 13, 37, 41, 46, 160, 269, 271 💬
384	Rheumatoid arthritis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
385	Rheumatoid arthritis 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
386	Rheumatoid arthritis 💬	1件: IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
387	Rheumatoid arthritis 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
388	Rheumatoid arthritis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
389	Rheumatoid arthritis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
390	RIG-I-like receptor signaling pathway 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
391	RIG-I-like receptor signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
392	RIG-I-like receptor signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
393	Salmonella infection 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
394	Salmonella infection 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
395	Salmonella infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
396	Salmonella infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
397	Shigellosis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
398	Shigellosis 💬	1件: IL1R1 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
399	Shigellosis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
400	Shigellosis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
401	Signaling pathways regulating pluripotency of stem cells 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
402	Signaling pathways regulating pluripotency of stem cells 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
403	Sphingolipid signaling pathway 💬	1件: OPRD1 💬	D02095 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
404	Sphingolipid signaling pathway 💬	1件: OPRD1 💬	D05113 💬	Naltrexone	13件: 6 , 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226 💬
405	Sphingolipid signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
406	Sphingolipid signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
407	Systemic lupus erythematosus 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
408	Systemic lupus erythematosus 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
409	Systemic lupus erythematosus 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
410	T cell receptor signaling pathway 💬	1件: PDCD1 💬	D10316 💬	Nivolumab	12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 💬
411	T cell receptor signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
412	T cell receptor signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
413	T cell receptor signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
414	Terpenoid backbone biosynthesis 💬	1件: FDPS 💬	D00939 💬	Alendronic acid	7件: 19, 41, 46, 50, 271, 274, 299 💬
415	Terpenoid backbone biosynthesis 💬	1件: FDPS 💬	D07119 💬	Alendronic acid	7件: 19, 41, 46, 50, 271, 274, 299 💬
416	TGF-beta signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
417	TGF-beta signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
418	Th1 and Th2 cell differentiation 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
419	Th1 and Th2 cell differentiation 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
420	Th1 and Th2 cell differentiation 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
421	Th1 and Th2 cell differentiation 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
422	Th17 cell differentiation 💬	1件: IL17A 💬	D09967 💬	Secukinumab	7件: 13, 37, 41, 46, 160, 269, 271 💬
423	Th17 cell differentiation 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
424	Th17 cell differentiation 💬	1件: IL1R1 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
425	Th17 cell differentiation 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
426	Th17 cell differentiation 💬	1件: IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
427	Th17 cell differentiation 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
428	Th17 cell differentiation 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
429	Th17 cell differentiation 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
430	Th17 cell differentiation 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
431	Th17 cell differentiation 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
432	Th17 cell differentiation 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
433	TNF signaling pathway 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
434	TNF signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
435	TNF signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
436	TNF signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
437	Toll-like receptor signaling pathway 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
438	Toll-like receptor signaling pathway 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
439	Toll-like receptor signaling pathway 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
440	Toll-like receptor signaling pathway 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
441	Toll-like receptor signaling pathway 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
442	Toll-like receptor signaling pathway 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
443	Toxoplasmosis 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
444	Toxoplasmosis 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
445	Toxoplasmosis 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
446	Toxoplasmosis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
447	Toxoplasmosis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
448	Transcriptional misregulation in cancer 💬	1件: CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
449	Transcriptional misregulation in cancer 💬	1件: IL1R2 💬	D02934 💬	Anakinra	19件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
450	Transcriptional misregulation in cancer 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
451	Tuberculosis 💬	3件: IL12A, IL12B, IL23A 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
452	Tuberculosis 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
453	Tuberculosis 💬	1件: IL23A 💬	D10438 💬	Guselkumab	4件: 37, 41, 96, 97 💬
454	Tuberculosis 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
455	Tuberculosis 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
456	Tuberculosis 💬	2件: JAK1, JAK2 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
457	Tuberculosis 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
458	Tuberculosis 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
459	Tuberculosis 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
460	Tuberculosis 💬	1件: VDR 💬	D01518 💬	Alfacalcidol	6件: 41, 46, 49, 50, 96, 235 💬
461	Type I diabetes mellitus 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
462	Type I diabetes mellitus 💬	2件: IL12A, IL12B 💬	D09214 💬	Ustekinumab	15件: 37, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 162, 269, 271 💬
463	Type I diabetes mellitus 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
464	Type I diabetes mellitus 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
465	Type I diabetes mellitus 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
466	Type II diabetes mellitus 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
467	Type II diabetes mellitus 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
468	Vascular smooth muscle contraction 💬	1件: EDNRA 💬	D01227 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
469	Vascular smooth muscle contraction 💬	1件: EDNRA 💬	D07538 💬	Bosentan	11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212 💬
470	VEGF signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
471	Viral carcinogenesis 💬	1件: JAK1 💬	D10308 💬	Baricitinib	9件: 41, 46, 49, 50, 93, 107, 265, 268, 325 💬
472	Viral carcinogenesis 💬	1件: JAK1 💬	D10994 💬	Upadacitinib	7件: 40, 41, 46, 49, 96, 97, 271 💬
473	Viral myocarditis 💬	2件: CD80, CD86 💬	D03203 💬	Abatacept	26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
474	Viral protein interaction with cytokine and cytokine receptor 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
475	Viral protein interaction with cytokine and cytokine receptor 💬	1件: IL6R 💬	D10161 💬	Sarilumab	5件: 41, 46, 84, 107, 271 💬
476	Viral protein interaction with cytokine and cytokine receptor 💬	1件: IL6R 💬	D02596 💬	Tocilizumab	18件: 2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
477	Viral protein interaction with cytokine and cytokine receptor 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
478	Viral protein interaction with cytokine and cytokine receptor 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬
479	Wnt signaling pathway 💬	5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬	D00184 💬	Cyclosporine	43件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 💬
480	Yersinia infection 💬	1件: IL1B 💬	D09911 💬	Gevokizumab	4件: 41, 50, 56, 269 💬
481	Yersinia infection 💬	1件: IL6 💬	D10080 💬	Sirukumab	2件: 41, 46 💬
482	Yersinia infection 💬	1件: TNF 💬	D02597 💬	Adalimumab	16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬
483	Yersinia infection 💬	1件: TNF 💬	D02598 💬	Infliximab	25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬

先頭へ